HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Tom Farrell, President and CEO, is scheduled to present at two healthcare investor conferences in November.
Credit Suisse 25th Annual Healthcare Conference
- Date: Monday, November 7, 2016
- Time: 11:30 a.m. MST
- Location: Scottsdale, AZ
Jefferies 2016 London Healthcare Conference
- Date: Wednesday, November 16, 2016
- Time: 4:40 p.m. GMT
- Location: London, UK
Live webcasts of each presentation may be accessed from the News & Events section of the Bellicum website. Archived versions will be available for replay for at least two weeks following each event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.